# US 10,501,547 B2 · ALK7 binding proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,547 B2
- Document ID: US10501547B2
- Status: Granted
- Kind: B2
- Application number: 15/494,081
- Filed: 2017-04-21
- Published: 2017-10-26
- Granted: 2019-12-10
- Earliest claimed: 2016-04-22
- Assignees: Acceleron Pharma Inc.; Adimab, LLC
- Applicants: Acceleron Pharma Inc.; Adimab, LLC
- Inventors: John Knopf; Jonathan Belk; Nathan J. Sharkey; Ravindra Kumar; Asya Grinberg; Dianne Sako; Roselyne Castonguay; Yossi Dagon
- Web page: https://patentgrep.com/patent/US10501547B2

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

## Claims

### Claim 1

An activin receptor-like kinase 7 (ALK7)-binding protein comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 105 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 110, wherein the protein binds to ALK7.

### Claim 2

An activin receptor-like kinase 7 (ALK7)-binding protein comprising a set of CDRs in which:
(i) VH-CDR1 comprises the amino acid sequence of SEQ ID NO: 102;
(ii) VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 103;
(iii) VH-CDR3 comprises the amino acid sequence of SEQ ID NO:104
(iv) VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 107;
(v) VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 108; and
(vi) VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 109;
wherein the protein binds to ALK7.

### Claim 3 (depends on 2)

The ALK7-binding protein of claim 2, wherein the ALK7-binding protein is an antibody, wherein the antibody is a monoclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a bi-specific antibody, a multi-specific antibody, or an ALK7-binding antibody fragment.

### Claim 4 (depends on 3)

The ALK7-binding protein of claim 3, wherein the ALK7-binding antibody fragment is a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.

### Claim 5 (depends on 3)

The ALK7-binding protein of claim 3, wherein the antibody further comprises a heavy chain immunoglobulin constant domain selected from the group consisting of:
(a) a human IgA constant domain;
(b) a human IgD constant domain;
(c) a human IgE constant domain;
(d) a human IgG1 constant domain;
(e) a human IgG2 constant domain;
(f) a human IgG3 constant domain;
(g) a human IgG4 constant domain; and
(h) a human IgM constant domain.

### Claim 6 (depends on 3)

The ALK7-binding protein of claim 3, wherein the antibody further comprises a light chain immunoglobulin constant domain selected from the group consisting of:
(a) a human Ig kappa constant domain; and
(b) a human Ig lambda constant domain.

### Claim 7 (depends on 3)

The ALK7-binding protein of claim 3, wherein the antibody further comprises a human IgG1 heavy chain constant domain and a human lambda light chain constant domain.